Preclinical Targeting of a GIT1–MAT2B Scaffold in Colon and Liver Cancer

Key takeaways:

• Study identifies a GIT1–MAT2B scaffold that supports tumor signaling in colorectal and liver cancer models
• Small molecule C3 disrupts this interaction by targeting GIT1
• Preclinical results show reduced proliferation, increased cell death, and decreased metastatic potential
• Further compound optimization is planned prior to potential clinical development

Researchers reporting in Cell Death & Disease describe a preclinical strategy targeting a protein–protein interaction between GIT1 and MAT2B, identifying a small molecule, C3, that disrupts this complex in colorectal and liver cancer models.

The study centers on GIT1 and MAT2B, two proteins found to be upregulated in colorectal and hepatocellular carcinoma systems. The investigators report that these proteins form a functional scaffold that supports oncogenic signaling, positioning the GIT1–MAT2B interaction as a potential therapeutic target. Rather than acting independently, the proteins appear to cooperate within this complex to promote tumor cell growth and survival.

To target this interaction, the research team developed and characterized C3, a small molecule designed to bind GIT1 and interfere with its association with MAT2B. The authors report that C3 disrupts the integrity of the scaffold, thereby impairing downstream signaling linked to tumor progression.

In preclinical models, treatment with C3 was associated with reduced cancer cell proliferation, increased cell death, and decreased metastatic behavior. These effects were observed across experimental systems evaluating colorectal and liver cancer, supporting the proposed role of the GIT1–MAT2B scaffold in maintaining tumor-promoting activity.

The findings suggest that disrupting protein scaffolds—rather than directly inhibiting individual proteins—may represent a viable therapeutic strategy in these cancers. The authors further note that elevated GIT1 expression has been observed across multiple tumor types, raising the possibility that this approach could have broader relevance beyond the models studied.

The study remains at an early, preclinical stage. The investigators indicate that further work will focus on optimizing C3 to improve its potency and drug-like properties. No detailed data on safety, toxicity, or clinical translation strategies were reported in the study.